Lightnews — Scholar-powered news

A-TANGO Project @a-tango.bsky.social · 5d

👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF!

#BenchToBedside #cirrhosis
@rajivjalan.bsky.social

1 2

A-TANGO Project @a-tango.bsky.social · Jul 28

For #WorldHepatitisDay we stand together 🩺

At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️

Every person deserves timely, effective, and #stigma‑free support 💪

@europeliver.bsky.social
@who.int

4 6

A-TANGO Project @a-tango.bsky.social · Jun 25

What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊

#AlcoholicHepatitis

@europeliver.bsky.social
@easlnews.bsky.social

4 7

A-TANGO Project @a-tango.bsky.social · May 28

Join this exciting event!

Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!

🚀 Register now: inevent.uk/en/Crowdheli...

3 6

A-TANGO Project @a-tango.bsky.social · May 20

The #LiverHealth Helix Event acts as a platform for sharing experiences regarding #DrugDevelopment challenges in #ClinialTrials + fostering collaboration between attendees.

Key Objectives:
🔵 Communicate A-TANGO’s results
🔵 Connect industry & scientific community
🔵 Showcase the Liver Health Helix

3

A-TANGO Project @a-tango.bsky.social · May 20

📣 Secure your spot now 📣:
inevent.uk/en/Crowdheli...

Check out our upcoming (online) A-TANGO #LiverHealth Helix Event!

🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials
🗓️ 04 June 2025
🕙 Begin: 10 am BST

#ClinicalResearch
@rajivjalan.bsky.social
@easlnews.bsky.social

1 2 4

A-TANGO Project @a-tango.bsky.social · May 12

We really appreciate the fantastic talk and continued collaboration with ELPA @europeliver.bsky.social! 🎉🙏

1

Reposted by A-TANGO Project

ELPA @europeliver.bsky.social · May 12

At #EASL2025, ELPA President Marko Korenjak presented 3 EU projects: A-TANGO, LIVER AIM & THRIVE.

At the Layperson Events, science met real stories — patients at the center of innovation, action & hope.

@liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social

1 4 4

A-TANGO Project @a-tango.bsky.social · May 12

Using this for the final #ConsensusConference of A-TANGO - to evaluate #GTAK trial outcomes & agree on the best treatment for #LiverPatients with #ACLF.

👉 The name comes from the ancient Greek „Oracle of Delphi“ 🔮🇬🇷

👉 The Delphi Method evolved during the Cold War for strategic military decisions 🕊️☮️

1 4

A-TANGO Project @a-tango.bsky.social · May 12

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.

🗓️ What a fun #workshop at #EASLCongress 2025

1 3 7

A-TANGO Project @a-tango.bsky.social · May 10

🧠 SAT-210 – #EASL2025

New tool alert!

The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!

#LiverHealth #HE #ClinicalResearch

3 5

A-TANGO Project @a-tango.bsky.social · May 10

🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis

3 5

A-TANGO Project @a-tango.bsky.social · May 10

👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress

👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?

Chair @rajivjalan.bsky.social

2 5

A-TANGO Project @a-tango.bsky.social · May 9

👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏

🥳 TOP-217-YI 🥳

Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications

2 5

Reposted by A-TANGO Project

EASL @easlnews.bsky.social · Mar 20

Today’s #readoftheweek📚 highlights the presence of inflammation and bacterial products in the systemic circulation in patients with compensated #cirrhosis and clinically significant portal hypertension.

Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...

#LiverSky

2 8

A-TANGO Project @a-tango.bsky.social · May 9

🥳 SATURDAY 🥳

If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité

#AlcoholicHepatitis #cirrhosis #ACLF #inflammation

@rajivjalan.bsky.social
@medblab.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social

A-TANGO Project @a-tango.bsky.social · Apr 25

Let’s talk #inflammation, #alcohol-related #hepatitis and new treatment strategies at #EASLCongress

👉 A-TANGO Networking Session
🗓️ Sat, 10 May 2025, 9:45–10:15
📍 Cirrhosis & Complications Track Hub

These short networking sessions are lots of fun! @easlnews.bsky.social

#hepatology #cirrhosis #ACLF

2 5

A-TANGO Project @a-tango.bsky.social · May 9

Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress:

FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium

Crucial for understanding the disease progression!
@rajivjalan.bsky.social

2 5

A-TANGO Project @a-tango.bsky.social · May 9

🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏

👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate

👍 In A-TANGO, we use #TAK242 + G-CSF